💊 Insulin aspart (Fiasp)
Insulin aspart (Fiasp) is a rapid-acting human insulin analog used to improve blood sugar control in adults and children with diabetes mellitus. It is given by subcutaneous injection or insulin pump, and in specific situations by intravenous infusion under medical supervision. Your doctor or pharmacist sets the dose that is right for you.
In Arabic: إنسولين أسبارت🏷️ Brand names & manufacturers
Packages shown are US-market (DailyMed). Brands available in Palestine are in the price section below.✅ What it is used for
- Improve glycemic control in adult and pediatric patients with diabetes mellitus
🧪 Active ingredient
Insulin aspart: an insulin analog that regulates glucose metabolism. It binds to insulin receptors, lowering blood glucose by facilitating glucose uptake into skeletal muscle and fat tissue and by inhibiting glucose output from the liver; it also inhibits lipolysis and proteolysis and enhances protein synthesis.
🌿 Benefits
- Lowers blood glucose and improves glycemic control
- Onset of effect about 16 to 20 minutes after injection in clinical pharmacology data
📝 How to use
- The dose is set and adjusted by your doctor or pharmacist based on your needs, blood glucose results and treatment goal; do not change it without consulting them
- Inject at the start of a meal or within 20 minutes after starting a meal, under the skin of the abdomen, upper arm, or thigh
- Rotate injection sites within the same region to reduce the risk of lipodystrophy and localized cutaneous amyloidosis; do not inject into affected areas
- Generally used together with an intermediate- or long-acting insulin
- May be used in an insulin pump according to the pump's instructions, after checking compatibility
- Intravenous infusion is given only under medical supervision after dilution
- Inspect before use: it should be clear and colorless; do not use if particles or discoloration are seen
- Do not mix with any other insulin, and check the insulin label before each injection
- If you forget a mealtime dose, check your blood glucose to decide whether an insulin dose is needed, then resume your usual schedule at the next meal
💊 Dosage forms
- Injection solution 100 units/mL (U-100)
- 10 mL multiple-dose vial
- 3 mL single-patient-use FIASP FlexTouch pen
- 3 mL single-patient-use PenFill cartridges
- 1.6 mL single-patient-use PumpCart cartridges for compatible insulin pumps
⚠️ Common side effects
- Hypoglycemia
- Injection/infusion site reactions
- Lipodystrophy
- Weight gain
- Nasopharyngitis and upper respiratory tract infection
- Nausea, diarrhea and back pain (in some trials)
- Urinary tract infection (in type 2 diabetes trial)
- Headache, fever, vomiting and influenza (in children)
🚨 Serious — seek medical help
- Severe, potentially life-threatening hypoglycemia
- Potentially life-threatening hypokalemia
- Severe hypersensitivity reactions, including generalized allergy and anaphylaxis
- Fluid retention and heart failure when used with thiazolidinediones (TZDs)
- Hyperglycemia and ketoacidosis due to insulin pump malfunction
⛔ Do not use if
- During episodes of hypoglycemia
- Known hypersensitivity to insulin aspart or any of its excipients
❗ Warnings & precautions
- Never share a FlexTouch pen, PenFill cartridge or PenFill cartridge device between patients, even if the needle is changed; do not share needles or syringes with vials, due to the risk of blood-borne pathogen transmission
- Changes in insulin regimen (strength, manufacturer, type, injection site or method of administration) should be made under close medical supervision with more frequent glucose monitoring
- Increase glucose monitoring with changes in dose, co-administered medications, meal pattern or physical activity, and in renal or hepatic impairment or hypoglycemia unawareness
- Insulin mix-ups can occur; check the label before each injection
- Monitor potassium in patients at risk of hypokalemia
- Watch for signs of heart failure when used with TZDs
- If the pump malfunctions, monitor glucose and inject subcutaneously
- Use the FlexTouch pen and PenFill cartridges with caution in patients with visual impairment who rely on audible clicks
- Pediatric patients with type 1 diabetes had a higher rate of hypoglycemic episodes than with NovoLog, especially at night; monitor glucose closely
🔄 Drug interactions
- Drugs that may increase hypoglycemia risk: other antidiabetic agents, ACE inhibitors, angiotensin II receptor blockers, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics
- Drugs that may decrease the glucose-lowering effect: atypical antipsychotics (e.g., olanzapine, clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics (e.g., albuterol, epinephrine, terbutaline), thyroid hormones
- Drugs that may increase or decrease the effect: alcohol, beta-blockers, clonidine, lithium salts; pentamidine may cause hypoglycemia sometimes followed by hyperglycemia
- Drugs that may blunt hypoglycemia symptoms: beta-blockers, clonidine, guanethidine, reserpine
- Dose adjustment and more frequent glucose monitoring may be required with these drugs
🤰 Pregnancy
There are no available data with Fiasp in pregnant women to assess the risk of major birth defects or miscarriage. Published randomized trials of insulin aspart used during the second trimester did not report an association with major birth defects or adverse maternal or fetal outcomes. Poorly controlled diabetes in pregnancy poses risks to mother and fetus, so consult your doctor.
🍼 Breastfeeding
The label text provided does not contain lactation information; consult your doctor before use while breastfeeding.
🧒 Children
Safety and effectiveness of Fiasp have been established to improve glycemic control in pediatric patients with diabetes mellitus (study in patients with type 1 diabetes aged 2 to 17 years). Pediatric patients had a higher rate of blood glucose confirmed hypoglycemic episodes than with NovoLog, especially at night, so blood glucose should be monitored closely.
👴 Older adults
No overall differences in safety or effectiveness were observed between elderly and younger adult patients, but caution is advised; initial dosing, dose increments and maintenance dosage should be conservative to avoid hypoglycemia.
🌡️ Storage
Unused vials: store in a refrigerator at 2°C to 8°C (36°F to 46°F), not in or near the freezing compartment. Never freeze and do not use if frozen. Protect from excessive heat and light and keep in the original carton. Do not draw into a syringe for later use. Keep the pen cap on to protect from light; remove the needle after each injection and use a new needle each time. In-use or unopened vials and FlexTouch pens may be kept for 28 days at room temperature (up to 30°C [86°F]).
⏰ Missed dose
If you miss a mealtime dose on a basal-bolus regimen, check your blood glucose to decide whether an insulin dose is needed, then resume your usual schedule at the next meal. Ask your doctor if unsure.
🆘 Overdose
Excess insulin may cause hypoglycemia and hypokalemia. Mild episodes are usually treated with oral glucose; dose, meal pattern or exercise adjustments may be needed. Severe episodes with coma, seizure or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary as hypoglycemia may recur. Hypokalemia must be corrected. Seek medical help immediately.
💰 Price & brands in your area
Local prices are currently available for Palestine; more countries are coming. Ask your pharmacist for local price and alternatives.
📍 Find the nearest pharmacy
Your location is used only in your browser to show nearby pharmacies — we don't store it.
Open in Google Maps👨⚕️ For healthcare professionals
Mechanism of action
Insulin aspart binds insulin receptors, increasing glucose uptake in skeletal muscle and adipose tissue and inhibiting hepatic glucose output; it inhibits lipolysis and proteolysis and enhances protein synthesis. It is a rapid-acting analog homologous to human insulin except for proline-to-aspartic acid substitution at B28, produced by recombinant DNA technology in Saccharomyces cerevisiae. Onset is about 16-20 minutes, peak effect about 91-133 minutes, and effect returns to baseline in about 5-7 hours depending on dose.
Labeled dosing
Individualize and adjust dosage based on route of administration, metabolic needs, blood glucose monitoring results and glycemic goal. Subcutaneous injection at the start of a meal or within 20 minutes after starting a meal, generally with an intermediate- or long-acting insulin. May be given by continuous subcutaneous infusion via pump, or intravenously under medical supervision after dilution to 0.5-1 unit/mL in polypropylene infusion bags. Dose adjustments may be needed when switching insulins or with changes in physical activity, concomitant medications, meal patterns, renal/hepatic function or acute illness. The FlexTouch pen dials in 1-unit increments.
- Contraindicated during hypoglycemia and with hypersensitivity to insulin aspart or excipients
- Risk of insulin product mix-ups: verify the label
- Monitor potassium in patients at risk for hypokalemia
- Observe for heart failure with TZDs; consider dose reduction or discontinuation
- In pump malfunction: monitor glucose and give subcutaneous injection
- Higher rate of hypoglycemia in pediatric patients vs NovoLog, especially nocturnal
- Conservative dosing in elderly patients
- Never share pens or cartridges between patients
🎓 Key points for students
- Fiasp (insulin aspart) contains niacinamide and L-arginine among its inactive ingredients
- Rapid-acting analog: proline replaced by aspartic acid at position B28
- Routes: subcutaneous, pump, and intravenous under supervision
- Key adverse effects: hypoglycemia, hypokalemia, hypersensitivity, lipodystrophy, weight gain
- Interactions: drugs increasing hypoglycemia risk, drugs reducing effect, and drugs blunting hypoglycemia symptoms (beta-blockers, clonidine, etc.)
- Management of hypoglycemia: oral glucose if mild; glucagon or IV glucose if severe
EME runs your whole clinic: appointments with WhatsApp reminders, patient files, finance & inventory, a patient portal and a members-price medical store — with your data isolated and protected.
Try EME free How we protect your data❓ FAQ
What is Fiasp (insulin aspart) used for?
It is used to improve blood sugar control in adults and children with diabetes mellitus.
When should Fiasp be injected relative to a meal?
At the start of a meal or within 20 minutes after starting a meal. Your doctor or pharmacist determines your dose.
Can it be mixed with another insulin?
No, Fiasp must not be mixed with any other insulin.
What are the main side effects?
The main ones are hypoglycemia, injection site reactions, lipodystrophy, weight gain, and allergic reactions.
How should I store it?
Store unused product in a refrigerator (2°C to 8°C) without freezing, away from heat and light. Once in use it may be kept up to 28 days at room temperature (up to 30°C [86°F]) or in the refrigerator.
Can I share my pen with someone else?
No. Never share pens, cartridges or needles, even if the needle is changed, because of the risk of transmitting infections.
⚕️ For education only — not a substitute for advice from your doctor or pharmacist. Do not start or stop any medicine without advice. Source: official FDA drug label via openFDA (2023-06), simplified. Updated: 2026-11-16.
Novolog Mix 70/30🏭 Novo Nordisk Pharmaceutical Industries, LP
Insulin Diluting Medium For Novolog🏭 Novo Nordisk
Fiasp🏭 Novo Nordisk
Insulin Aspart Protamine And Insulin Aspart Mix 70/30🏭 Novo Nordisk Pharma, Inc.
Insulin Aspart🏭 Novo Nordisk Pharma, Inc.